CorVel/$CRVL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CorVel
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
- Ticker
- $CRVL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 5,239
- Headquarters
- Fort Worth, United States
- Website
- www.corvel.com
CorVel Metrics
BasicAdvanced
$4.3B
36.02
$2.38
1.08
-
Price and volume
Market cap
$4.3B
Beta
1.08
52-week high
$89.76
52-week low
$44.83
Average daily volume
184K
Financial strength
Current ratio
2.023
Quick ratio
1.47
Long term debt to equity
0.06
Total debt to equity
0.06
Profitability
EBITDA (TTM)
194.991
Gross margin (TTM)
25.53%
Net profit margin (TTM)
12.02%
Operating margin (TTM)
15.93%
Effective tax rate (TTM)
24.59%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
15.20%
Return on equity (TTM)
30.64%
Valuation
Price to earnings (TTM)
36.024
Price to revenue (TTM)
4.329
Price to book
10.09
Price to tangible book (TTM)
11.2
Growth
Revenue change (TTM)
8.29%
Earnings per share change (TTM)
18.07%
3-year revenue growth (CAGR)
10.44%
10-year revenue growth (CAGR)
7.11%
3-year earnings per share growth (CAGR)
18.58%
10-year earnings per share growth (CAGR)
17.64%
Bulls say / Bears say
Growth is translating into stronger profits: Q2 FY27 revenue rose 11% year on year and diluted EPS rose 24%, while gross margin widened from 24% to 27%. That points to operating leverage as the business scales. (SEC)
New customer wins and deeper client relationships are adding growth opportunities, including another top-10 health plan implementation and a partnership that opens access to the Blue Cross Blue Shield market. New prepayment products could also help CorVel extend its reach with large payers. (CorVel)
CorVel ended the quarter with $270 million in cash and no borrowings, while repurchasing $18.1 million of shares. This strong balance sheet provides financial flexibility and supports shareholder returns. (SEC)
The shares trade at about 35 times trailing earnings, leaving limited room for disappointment if growth or margin expansion slows. The valuation therefore depends on strong earnings compounding continuing. (AInvest)
CorVel faces exposure to falling workers’ compensation claims, tougher pricing and customers bringing services in-house. Any of these could weaken demand for its services and make revenue growth less reliable. (SEC)
Labour and benefit inflation could squeeze margins if CorVel cannot pass higher costs on to clients. Its latest filing also flags price pressure, making cost control important even while the company is growing. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
CorVel Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
Funds containing CorVel
AllUSDEURGBP
Fund name | Fund size | $CRVL weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.25% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.25% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.25% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.15% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.